Aripiprazole (Synonyms: OPC 31, OPC 14597) |
| Catalog No.GC10117 |
5-HT receptor partial agonist
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 129722-12-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Aripiprazole is a novel and atypical antipsychotic [1].
Aripiprazole has been found to be a dopamine-serotonin system stabilizer with potent partial agonist activity at dopamine D2 and 5-HT1A receptors and antagonist activity at 5-HT2A receptors. In addition, aripiprazole has been reported to label with the agonist [125I]7-OH-PIPAT and with the antagonist [3H]spiperone with 0.34±0.02nM and 0.70±0.22nM, respectively. Besides, aripiprazole has been revealed to dose-dependently and potently inhibit the increase in cAMP accumulation stimulated by forskolin in CHO cells and HEK-293 cells. Other results have also been reported that aripiprazole completely inhibited the increase GTPase activity stimulated by the D2 receptor agonist quinpirole in rat striatal membranes [1].
References:
[1] Burris KD1, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002 Jul; 302(1):381-9.
Average Rating: 5 (Based on Reviews and 37 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *